Newly Listed Lenz Therapeutics' Vision Loss Experimental Drug Meets Primary Goal In Late-Stage Study

on MSN ago, source:

On Wednesday, LENZ Therapeutics Inc (NASDAQ:LENZ) released topline results from its Phase 3 CLARITY study of two ...

Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says

15d ago, source:

Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hours, it offers a promising alternative to reading glasses. Analysts predict a ...

LENZ Therapeutics Inc LENZ

7d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

24d ago, source: Enid News & Eagle

LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been ...

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

23d ago, source: Stockhouse

LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first ...

LENZ Therapeutics' Late-stage Study Of LNZ100 In Presbyopia Meets Primary Goal; Stock Rises

23d ago, source: Business Insider

(RTTNews) - LENZ Therapeutics, Inc. (LENZ) Wednesday announced positive results from the Phase 3 CLARITY study of its two drug candidates LNZ100 and LNZ101, for the treatment of presbyopia ...

LENZ Therapeutics, Inc. Common Stock (LENZ)

17d ago, source: Nasdaq

Nasdaq provides press releases highlighting valuable information sent out by companies. Here you can find the company’s latest financial figures, contact information, and source version of the ...

Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says

15d ago, source: Hosted on MSN

Last week, LENZ Therapeutics Inc (NASDAQ:LENZ) released topline results from its Phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101. Lead product candidate ...

LENZ Therapeutics Inc

10d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

LENZ Therapeutics, Inc. Common Stock (LENZ)

17d ago, source: Nasdaq

Nasdaq provides company’s SEC filings, which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC ...

Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says

15d ago, source: Benzinga.com

Citigroup has initiated coverage on LENZ Therapeutics with a Buy rating and ... potentially replacing the need for reading glasses. AbbVie Inc’s ABBV Vuity validated this market, but its ...